Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
Prime Medicine (Nasdaq: PRME) has secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to accelerate the development of Prime Editors for treating cystic fibrosis (CF). The funding includes a $6 million equity investment and will be provided in two tranches, subject to certain conditions and milestones.
The company's Prime Editing technology aims to permanently correct CF-related lung disease through multiple hotspot Prime Editors that could potentially benefit over 93% of CF patients. Initially, Prime Medicine will focus on targeting the G542X mutation, one of the most common CF-causing nonsense mutations currently lacking available therapies.
Prime Medicine (Nasdaq: PRME) ha ottenuto fino a 24 milioni di dollari di finanziamenti aggiuntivi dalla Cystic Fibrosis Foundation per accelerare lo sviluppo dei Prime Editors per il trattamento della fibrosi cistica (CF). Il finanziamento comprende un investimento azionario di 6 milioni di dollari e sarà erogato in due tranche, soggette a determinate condizioni e obiettivi.
La tecnologia Prime Editing dell'azienda mira a correggere in modo permanente la malattia polmonare correlata alla CF attraverso diversi Prime Editors specifici per le mutazioni più frequenti, potenzialmente utili a oltre il 93% dei pazienti con CF. Inizialmente, Prime Medicine si concentrerà sul targeting della mutazione G542X, una delle mutazioni nonsense più comuni che causano CF e per la quale attualmente non esistono terapie disponibili.
Prime Medicine (Nasdaq: PRME) ha asegurado hasta 24 millones de dólares en financiamiento adicional de la Cystic Fibrosis Foundation para acelerar el desarrollo de Prime Editors para el tratamiento de la fibrosis quística (FQ). El financiamiento incluye una inversión de capital de 6 millones de dólares y se proporcionará en dos tramos, sujetos a ciertas condiciones y hitos.
La tecnología Prime Editing de la compañía tiene como objetivo corregir permanentemente la enfermedad pulmonar relacionada con la FQ mediante múltiples Prime Editors dirigidos a puntos calientes, que podrían beneficiar potencialmente a más del 93% de los pacientes con FQ. Inicialmente, Prime Medicine se enfocará en atacar la mutación G542X, una de las mutaciones nonsense más comunes que causan FQ y que actualmente no cuenta con terapias disponibles.
Prime Medicine (나스닥: PRME)는 낭포성 섬유증(CF) 치료를 위한 Prime Editors 개발 가속화를 위해 낭포성 섬유증 재단으로부터 최대 2,400만 달러의 추가 자금을 확보했습니다. 이 자금에는 600만 달러의 지분 투자가 포함되어 있으며, 특정 조건과 이정표에 따라 두 차례에 걸쳐 제공될 예정입니다.
회사의 Prime Editing 기술은 여러 주요 변이에 대응하는 Prime Editors를 통해 CF 관련 폐 질환을 영구적으로 교정하는 것을 목표로 하며, 이는 93% 이상의 CF 환자에게 잠재적으로 혜택을 줄 수 있습니다. 초기에는 Prime Medicine이 현재 치료법이 없는 가장 흔한 CF 원인 무의미 돌연변이 중 하나인 G542X 변이를 표적으로 삼을 예정입니다.
Prime Medicine (Nasdaq : PRME) a obtenu jusqu'à 24 millions de dollars de financement supplémentaire de la Cystic Fibrosis Foundation pour accélérer le développement des Prime Editors destinés à traiter la fibrose kystique (FK). Ce financement comprend un investissement en actions de 6 millions de dollars et sera versé en deux tranches, sous réserve de certaines conditions et étapes clés.
La technologie Prime Editing de l'entreprise vise à corriger de manière permanente la maladie pulmonaire liée à la FK grâce à plusieurs Prime Editors ciblant des hotspots, pouvant potentiellement bénéficier à plus de 93 % des patients atteints de FK. Initialement, Prime Medicine se concentrera sur la mutation G542X, l'une des mutations nonsense les plus courantes causant la FK et pour laquelle il n'existe actuellement aucun traitement disponible.
Prime Medicine (Nasdaq: PRME) hat von der Cystic Fibrosis Foundation bis zu 24 Millionen US-Dollar an zusätzlicher Finanzierung erhalten, um die Entwicklung von Prime Editors zur Behandlung der Mukoviszidose (CF) zu beschleunigen. Die Finanzierung umfasst eine 6-Millionen-Dollar-Beteiligungsinvestition und wird in zwei Tranchen unter bestimmten Bedingungen und Meilensteinen bereitgestellt.
Die Prime Editing-Technologie des Unternehmens zielt darauf ab, die CF-bedingte Lungenerkrankung dauerhaft zu korrigieren, indem mehrere Hotspot-Prime-Editoren eingesetzt werden, die potenziell über 93 % der CF-Patienten zugutekommen könnten. Zunächst wird sich Prime Medicine auf die G542X-Mutation konzentrieren, eine der häufigsten nonsense-Mutationen, die CF verursachen und für die derzeit keine Therapien verfügbar sind.
- None.
- Funding is subject to certain closing conditions and scientific milestones
- Initial focus limited to single mutation (G542X)
Insights
CF Foundation's $24M additional funding validates Prime Medicine's gene editing technology as a potential breakthrough for cystic fibrosis treatment.
Prime Medicine has secured up to
The funding structure includes two tranches contingent on scientific milestones, with the first tranche including a
What makes this development scientifically significant is Prime Medicine's approach targeting multiple CF-causing mutations. Their initial focus on the G542X nonsense mutation addresses an important unmet need, as patients with this mutation currently have no effective treatment options. Their "hotspot" editing approach could potentially benefit
For context, the CF market has been transformed by Vertex Pharmaceuticals' CFTR modulators, which generated over
This expanded partnership reflects Prime Medicine's strategic approach to capital allocation, leveraging non-dilutive funding to advance multiple programs simultaneously while preserving cash runway. The CF Foundation's continued financial commitment after their initial investment suggests the preclinical data has met or exceeded expectations, though specific milestone achievements weren't disclosed.
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) --
-- Prime Medicine to receive up to
-- Multiple hotspot Prime Editors may benefit more than
CAMBRIDGE, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to
The CF Foundation’s additional investment builds on initial funding received under Prime Medicines’ January 2024 agreement, and reflects its interest in Prime Editing as a potentially curative approach for CF. Prime Editing can correct a wide range of genetic mutations, and Prime Medicine intends to leverage the technology’s versatility and modularity to address multiple disease-causing mutations, potentially treating the vast majority of people with CF. Prime Medicine will initially focus on a program targeting G542X, one of the most prevalent CF-causing nonsense mutations and one for which there are no available therapies. In addition, the Company will continue to advance hotspot and PASSIGE-based approaches for other mutations with funding received from the CF Foundation under its initial commitment in 2024.
“We are honored to receive continued support from the CF Foundation, whose longstanding commitment to driving innovation has reshaped the treatment landscape for people living with CF,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “This additional funding reflects our shared belief in the transformative potential of Prime Editing therapy for people with this devastating genetic disease, especially for those where the current standard of care is either ineffective or poorly tolerated. This funding also exemplifies our strategic approach to business development, and our commitment within Prime Medicine to leveraging external resources to accelerate innovation and ensure the broadest application of our technology.”
The CF Foundation will provide Prime Medicine with up to
About Cystic Fibrosis
Cystic fibrosis (CF) is a serious, inherited genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. These mutations result in reduced or absent function of the CFTR protein, which is critical for maintaining the balance of salt and fluids across epithelial surfaces in organs such as the lungs, pancreas, and gastrointestinal tract. When CFTR is not functioning properly, thick, sticky mucus accumulates, leading to chronic lung infections, progressive respiratory decline, and impaired digestion and nutrient absorption. CF affects approximately 100,000 people globally, including over 40,000 in the United States. While disease-modifying therapies have improved outcomes for many individuals, they are not curative and are ineffective for some people with certain mutations. There remains a significant unmet need for a one-time, potentially curative treatment that can address the underlying genetic cause of CF across diverse genotypes.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the agreement with the CF Foundation and the intended and potential benefits thereof, including the receipt of payments based on scientific milestones; the potential for Prime Editing to correct the causative mutations of diseases, including CF; the potential for Prime Editing to treat the vast majority of people with CF; the continued advancement of hotspot and PASSIGE-based approaches for correcting mutations other than G542X; the breadth of Prime Editing technology and the implementation of its strategic plans for its business, programs, and technology; and the potential of Prime Editing as a transformative gene editing technology and its ability to unlock opportunities across thousands of potential indications
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to Prime Medicine’s product candidates entering clinical trials; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology; Prime Medicine’s ability to identify and enter into future license agreements and collaborations; Prime Medicine’s expectations regarding the anticipated timeline of its cash runway and future financial performance; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
FAQ
How much additional funding did Prime Medicine (PRME) receive from the Cystic Fibrosis Foundation?
What percentage of Cystic Fibrosis patients could Prime Medicine's treatment potentially help?
Which specific CF mutation is Prime Medicine initially targeting?
How will the CF Foundation distribute the funding to Prime Medicine (PRME)?
What is the purpose of Prime Medicine's Prime Editing technology for CF?
